Elevating GLP-1 receptor agonist adoption in India: A comprehensive review integrating the CLIBS framework and rogers’ model of diffusion

India faces a pressing epidemic of diabetes and obesity, driven by changing lifestyles, suboptimal dietary habits, and a lack of widespread preventive measures. Although GLP-1 receptor agonists (GLP-1 RAs) hold significant promise for improving glycemic control and supporting weight loss, their adoption in India remains suboptimal. Key barriers include high treatment costs, insufficient insurance coverage, limited patient and provider awareness, and cultural stigma toward injectable therapies.

This review synthesizes existing challenges and proposes an integrated approach to enhancing GLP-1 RA adoption in India by combining the CLIBS model—Cost-effectiveness, Long-term data, Insurance, Long-term benefits, and social media impact—with Rogers’ Diffusion of Innovations framework. Together, these models offer a structured, evidence-based roadmap for stakeholders, including policymakers, healthcare professionals, pharmaceutical companies, and patient advocacy groups, to overcome financial, social, and systemic barriers to GLP-1 RA use. By uniting economic strategies, robust data, insurance reforms, patient-centered education, and strategic social media engagement, this integrated approach can propel broader acceptance of GLP-1 RAs, mitigating India’s growing burden of diabetes and obesity.